Related Experiment Videos
[Vascular effects of adenosine-triphosphate]
1Département d'Anesthésie-Réanimation B, Hôpital Saint-Eloi, Montpellier.
Annales Francaises D'Anesthesie Et De Reanimation
|January 1, 1991
Summary
Adenosine triphosphate (ATP) causes dose-related vasodilation during cardiac surgery's hypothermic cardiopulmonary bypass. This finding is crucial for managing vascular resistance in patients undergoing heart surgery.
Area of Science:
- Cardiovascular Physiology
- Pharmacology
- Cardiac Surgery
Background:
- Systemic vascular resistance management is critical during hypothermic cardiopulmonary bypass.
- Adenosine triphosphate (ATP) is an endogenous nucleoside with known vasodilatory properties.
Purpose of the Study:
- To assess the effects of adenosine triphosphate (ATP) on systemic vascular resistance.
- To evaluate ATP's impact during the hypothermic cardiopulmonary bypass phase of cardiac surgery.
Main Methods:
- Randomized controlled trial with 20 patients undergoing cardiac surgery.
- Patients were divided into ATP (n=10) and placebo (n=10) groups.
- ATP or placebo was infused into the oxygenator's venous line at escalating doses (0.012-0.05 mg.kg-1.min-1).
- Mean arterial pressure (MAP) and pump flow rate (DP) were monitored; systemic vascular resistance calculated (MAP/DP).
Main Results:
- ATP induced a dose-related decrease in Mean Arterial Pressure (MAP).
- MAP decreased from 82.8 mmHg (control) to 49.0 mmHg at the highest ATP dose.
- No significant changes in pump flow rate (DP) or venous return were observed.
- MAP returned to baseline levels after ATP infusion cessation.
Conclusions:
- Adenosine triphosphate (ATP) effectively causes vasodilation during hypothermic cardiopulmonary bypass.
- ATP administration leads to a predictable, dose-dependent reduction in systemic vascular resistance.
- ATP may be a useful agent for managing vascular tone in cardiac surgery patients.